Aspira Women’s Health (NASDAQ:AWH) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Aspira Women’s Health (NASDAQ:AWH) from a sell rating to a hold rating in a research report released on Tuesday morning.

Separately, Alliance Global Partners lowered their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a buy rating for the company in a research note on Wednesday, August 14th.

Aspira Women’s Health Price Performance

Shares of NASDAQ AWH opened at $0.83 on Tuesday. The business’s 50 day moving average is $1.06 and its two-hundred day moving average is $2.02. Aspira Women’s Health has a 52-week low of $0.74 and a 52-week high of $6.01. The firm has a market cap of $13.25 million, a price-to-earnings ratio of -0.57 and a beta of 1.48.

Aspira Women’s Health (NASDAQ:AWH) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. The firm had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $2.60 million. During the same quarter in the prior year, the firm posted ($0.28) EPS. Analysts anticipate that Aspira Women’s Health will post -1.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its position in Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 236,396 shares of the company’s stock after acquiring an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent quarter. Institutional investors and hedge funds own 12.19% of the company’s stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.